Trial · NCT04008069
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Open-Label Period | STARTED | Open-Label Sarilumab (Pre-randomization) | 15 | |
| Open-Label Period | STARTED | Double-Blind Sarilumab (Post-randomization) | 0 | |
| Open-Label Period | STARTED | Double-Blind Placebo (Post-randomization) | 0 | |
| Open-Label Period | Completed Treatment up to Week 16 | Open-Label Sarilumab (Pre-randomization) | 10 | |
| Open-Label Period | Completed Treatment up to Week 16 | Double-Blind Sarilumab (Post-randomization) | 0 | |
| Open-Label Period | Completed Treatment up to Week 16 | Double-Blind Placebo (Post-randomization) | 0 | |
| Open-Label Period | COMPLETED | Open-Label Sarilumab (Pre-randomization) | 10 | |
| Open-Label Period | COMPLETED | Double-Blind Sarilumab (Post-randomization) | 0 | |
| Open-Label Period | COMPLETED | Double-Blind Placebo (Post-randomization) | 0 | |
| Open-Label Period | NOT COMPLETED | Open-Label Sarilumab (Pre-randomization) | 5 | |
| Open-Label Period | NOT COMPLETED | Double-Blind Sarilumab (Post-randomization) | 0 | |
| Open-Label Period | NOT COMPLETED | Double-Blind Placebo (Post-randomization) | 0 | |
| Randomized-Withdrawal Period | STARTED | Open-Label Sarilumab (Pre-randomization) | 0 | |
| Randomized-Withdrawal Period | STARTED | Double-Blind Sarilumab (Post-randomization) | 2 | |
| Randomized-Withdrawal Period | STARTED | Double-Blind Placebo (Post-randomization) | 8 | |
| Randomized-Withdrawal Period | Completed Treatment With Study Drug | Open-Label Sarilumab (Pre-randomization) | 0 | |
| Randomized-Withdrawal Period | Completed Treatment With Study Drug | Double-Blind Sarilumab (Post-randomization) | 1 | |
| Randomized-Withdrawal Period | Completed Treatment With Study Drug | Double-Blind Placebo (Post-randomization) | 5 | |
| Randomized-Withdrawal Period | COMPLETED | Open-Label Sarilumab (Pre-randomization) | 0 | |
| Randomized-Withdrawal Period | COMPLETED | Double-Blind Sarilumab (Post-randomization) | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04008069/flow